Pricing Index · Updated April 28, 2026
Mounjaro Cost in 2026: Brand vs Compounded Tirzepatide
Eli Lilly's list price for Mounjaro is about $1,023/mo cash-pay. Most patients pay much less. Below is the full picture: Lilly Direct, savings programs, branded telehealth ($69 to $450/mo), and compounded tirzepatide ($132 to $600/mo).
1. Eli Lilly direct pricing
In 2024 Eli Lilly launched Lilly Direct, a self-pay vial program designed to undercut compounded tirzepatide. Vial pricing as of April 2026:
- 2.5 mg vial: about $349/mo (4 vials)
- 5 mg vial: about $499/mo (4 vials)
- 7.5 mg and higher: not sold via direct vials, only as branded auto-injector pens at full list price
The vials require you to draw and inject yourself with a syringe, which is one reason some patients still prefer the pens. The savings program (different from Lilly Direct) brings eligible commercial-insurance patients to about $25/mo for the auto-injector pens.
2. Branded tirzepatide programs we track
We track 28 telehealth and clinic programs offering branded tirzepatide (Mounjaro or Lilly Direct). Sorted by monthly cost:
| Provider | Program | $/mo | Insurance | HSA/FSA |
|---|---|---|---|---|
| Livea | GLP-1 Plan | $69 | No | Yes |
| WeightWatchers Clinic | WeightWatchers Clinic | $74 | Yes | No |
| Hello Alpha | Weight Loss Plus+ | $79 | Yes | No |
| Sesame | Success by Sesame | $99 | Yes | Yes |
| Everlywell | Weight Care+ | $99 | No | Yes |
| Mayo Clinic Diet | Clinical Subscription | $100 | No | Yes |
| GoodRx | GoodRx for Weight Loss | $119 | No | Yes |
| Spartan Medical Associates | GLP-1 Weight Loss | $125 | No | No |
| Form Health | Obesity Medicine Program | $149 | Yes | Yes |
| TeleSlim Clinic | Monthly Subscription | $149 | No | No |
| Genesis Lifestyle Medicine | Medical Weight Loss | $150 | No | Yes |
| Mochi Health | Mochi Weight Loss | $178 | Yes | Yes |
| Rivas Medical Weight Loss | GLP-1 Program | $195 | No | Yes |
| CentroMed Weight Management | Medical Weight Management | $199 | Yes | Yes |
| Livea | Livea Complete | $199 | No | Yes |
| Fella Health | GLP-1 Program | $199 | Yes | Yes |
| MoKan Weight Loss | GLP-1 Medical Weight Loss | $200 | Yes | Yes |
| Rejuvime Medical | GLP-1 Weight Loss | $250 | No | No |
| Red Mountain Weight Loss | RM3 Program | $299 | No | Yes |
| Physicians Weight Loss Centers | GLP-1 Weight Loss Program | $299 | Yes | Yes |
| RCMC Medical Center | Medical Weight Loss Program | $299 | No | Yes |
| HormoneSynergy | Weight Loss for Longevity | $300 | No | No |
| Valley Medical Weight Loss | GLP-1 Medical Weight Loss | $325 | No | Yes |
| Options Medical Weight Loss | GLP-1 Weight Loss | $349 | Yes | Yes |
| JumpstartMD | Medical Weight Loss with GLP-1 | $349 | Yes | Yes |
| UCHealth Weight Loss Clinic | Medical Weight Management | $375 | Yes | Yes |
| Medi-Weightloss | Signature Program | $399 | Yes | Yes |
| NYU Langone Weight Management | Weight Management Program | $450 | Yes | Yes |
See the full pricing index for methodology and CSV download.
3. Compounded tirzepatide alternative
Compounded tirzepatide is the same molecule as Mounjaro, made by 503A or 503B compounding pharmacies under a personalized-prescription doctrine. It is significantly cheaper. We track 52 programs:
Cheapest compounded tirzepatide: Maximus at $132/mo. See provider profile.
The legal path is narrower in 2026 than during the FDA shortage (which ended October 2024). Personalized-prescription compounding remains legal in most states, but the FDA has signaled increased enforcement. Read our guide on brand vs compounded for the full picture.
4. Mounjaro dosing cost ladder
Brand-name Mounjaro pen pricing scales with dose volume rather than dose strength. The list price of about $1,023/mo applies to all six doses (2.5, 5, 7.5, 10, 12.5, 15 mg). Lilly Direct vials only sell the lower two doses (2.5 and 5 mg) self-pay.
If you titrate to 7.5 mg or higher and want to keep cash-pay costs down, your options are:
- Compounded tirzepatide at the equivalent dose
- Switching to Zepbound (FDA-approved for obesity, sometimes covered by insurance)
- Manufacturer savings card if you have commercial insurance
5. Insurance and savings programs
Mounjaro is FDA-approved for type 2 diabetes only. Off-label weight-loss prescriptions are usually denied by commercial insurers. Two paths:
- Diagnosis-based coverage: if you have type 2 diabetes or A1C above 6.5, your plan likely covers Mounjaro at a copay between $25 and $200/mo.
- Mounjaro savings card: commercial-insurance patients pay as little as $25/mo for up to 13 fills per year. Federal-program patients (Medicare, Medicaid, VA) are excluded.
For weight-loss-only prescriptions, Zepbound (same molecule, different FDA indication) is more likely to be covered.
FAQ
How much does Mounjaro cost without insurance in 2026?
Eli Lilly's list price for Mounjaro is about $1,023/mo. Through the Lilly Direct vial program you can pay $349 to $499/mo depending on dose. Branded tirzepatide telehealth programs in our index range $69 to $450/mo, median $199/mo.
Is compounded tirzepatide cheaper than Mounjaro?
Yes. Compounded tirzepatide ranges $132 to $600/mo across 52 programs we track, median $279/mo. Roughly half to one third the cost of brand-name Mounjaro.
Does insurance cover Mounjaro for weight loss?
Most US insurers cover Mounjaro for type 2 diabetes (its FDA-approved use) but deny coverage for off-label weight loss. For weight loss specifically, Zepbound (same molecule, approved for obesity) has a higher chance of being covered if your plan has obesity-medication benefits.
What is the cheapest way to get Mounjaro in 2026?
Three options: Lilly Direct vials ($349 to $499/mo through lilly.com/direct), the savings card if you have commercial insurance ($25/mo for eligible patients), or compounded tirzepatide through a licensed telehealth provider ($132 to $600/mo).
Has Mounjaro been removed from the FDA shortage list?
Yes. The FDA declared the tirzepatide shortage resolved in October 2024. After a court-ordered grace period, 503A compounding pharmacies were instructed to wind down compounding by March 2025. Some providers continue under personalized-prescription doctrines, but the regulatory path is narrower than during the shortage period.
Sources
- Eli Lilly Direct pricing page (lilly.com/direct), accessed April 2026
- FDA Drug Shortages database, tirzepatide injection status update (October 2024)
- Eli Lilly investor materials, savings program eligibility (2025)